The tumor microenvironment (TME) is essential for immune escape by tumor cells. It plays
essential roles in tumor development and metastasis. The clinical outcomes of tumors are …

Simple Summary Approved chimeric antigen receptor (CAR) T cells recognize and bind to
only one tumor target (single-targeted CAR T cells, Si-CART) on cancer cells by the special …

PURPOSE A combination of anti–B-cell maturation antigen (BCMA) and anti-CD19 chimeric
antigen receptor (CAR) T cells induced high response rates in patients with relapsed or …

Few prospective studies have examined posttransplant chimeric antigen receptor (CAR) T
cell infusion as candidates for front‐line consolidation therapy for high‐risk multiple …

Background Chimeric antigen receptor (CAR) T-cell therapy has proven to be a valuable
new treatment option for patients with B-cell malignancies. However, by applying selective …

Anti-CD30 CAR-T is a potent candidate therapy for relapsed/refractory (r/r) CD30+
lymphomas with therapy limitations, and the efficacy needed to be further improved. Herein …

Chimeric antigen receptor (CAR) T-cell therapies have achieved remarkable success in the
treatment of haematological malignancies. Over the past 9 years, the use of CAR T-cell …

Patients with multiple myeloma who are refractory to currently available effective therapies
have short expected survival. Modalities harvesting the knowledge of the immune …

Context.—The process for identifying patients with monoclonal gammopathies is complex.
Initial detection of a monoclonal immunoglobulin protein (M protein) in the serum or urine …

Background Recently, chimeric antigen receptor-modified (CAR) T cell therapy for
hematological malignancies has shown clinical efficacy. Hundreds of clinical trials have …